Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
04/07/2022 - 07:30 AM
WEST CHESTER, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022 at 3:00 p.m. ET.
Participants may access a live webcast of the event through the following link: https://w sw.com/webcast/needham117/vrca/2246788 .
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com . The webcast replay will be available shortly after conclusion of the event for 30 days.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit www.verrica.com .
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
William Windham Solebury Trout 646.378.2946 wwindham@soleburytrout.com
Terry Kohler Chief Financial Officer 484.453.3296 info@verrica.com
Media: Zara Lockshin Solebury Trout 646.378.2960 zlockshin@soleburytrout.com
Verrica Pharmaceuticals Inc
VRCA Rankings
#576 Ranked by Stock Gains
VRCA Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
US
City
West Chester
About VRCA
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.